Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States. Steqeyma, a ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Background The broad-spectrum antiparasitic drug ivermectin is widely used in children, and its use in children weighing < 15 kg is off-label, as little data is available to inform the use of ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.

Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Stelara® in patients with moderate to severe plaque psoriasis. Otulfi was approved for ...

J&J suing Samsung Bioepis over Stelara biosimilar Johnson & Johnson (JNJ) filed a suit against Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug ...

"Stelara has long been a cornerstone treatment ... Today's announcement is the latest of several initiatives designed to reduce drug costs, while preserving control and choice for payers ...

In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug. Ivonescimab, the new drug, was found in a trial ...

They were one of the biggest boy bands of the late '90s and early noughties, with three Number 1 singles and a chart-topping album to their name, and now Five appear to be teasing some big news.

The vibes are shifting on Wall Street. Popular gauges of investor sentiment are showing that the pervasive sense of optimism that followed President Donald Trump’s election victory in November ...